OBJECTIVE： To investigate the effects of Tiaojingzhuyun capsules on endometrial receptivity in mice with implantation dysfunction and corresponding mechanism. METHODS： Pregnant mice were randomized into normal group， model group and the groups of low and high-dose [12， 24 g/（kg·d）] Tiaojingzhuyun capsules， with 10 mice in each group. The mice in the drug administration groups were given corresponding drugs intragastrically， while those in the normal group and the model group were given normal saline intragastrically， for 3 consecutive days from the 1st day of pregnancy. On the 4th day of pregnancy， the mice in all groups except for the normal group were given mifepristone solution subactaneously to establish model of implantation dysfunction. On the 5th day of pregnancy， the mice were sacrificed， and then the change in endometrial morphology was observed and endometrial maturity was scored； the protein expression levels of leukaemia inhibitory factor （LIF）， homoeobox gene HOXA10， matrix metalloproteinase 9 （MMP-9） and matrix metalloproteinase inhibitory factor 1 （TIMP-1） expression in endometrial tissues were determined. RESULTS： Compared to the normal group， the mice in the model group and the drug administration groups had endometrial hypoplasia and obviously lower endometrial maturity score and protein expression levels of LIF， HOXA10， MMP-9 and TIMP-1 in endometrial tissues （P＜0.05）. Compared to the model group， the mice in the drug administration groups demonstrated endometrial development which improved or tended to be normal and had significantly higher indexes mentioned above （P＜0.05）； besides， the effect shown in the group of high-dose Tiaojingzhuyun capsules was stronger than that in the group of low-dose Tiaojingzhuyun capsules （P＜0.05）. CONCLUSIONS： Tiaojingzhuyun capsules can improve the endometrial receptivity in mice with implantation dysfunction by a mechanism which may be related to upregulating the gene expression of HOXA10 and LIF， and maintaining the balance of MMP-9 and TIMP-1.